PI3King on MYCN to improve neuroblastoma therapeutics

Cancer Cell
Michael D Hogarty, John M Maris

Abstract

MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN.

References

Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades

❮ Previous
Next ❯

Citations

Dec 11, 2013·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Maryam MonajemzadehMojgan Karbakhsh
Mar 27, 2015·Journal of Pediatric Hematology/oncology·David KingHelen E Bryant
Mar 24, 2012·Cancer Cell·Zhihui Liu, Carol J Thiele
Jan 7, 2019·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Andy Chi-Lung LeeJi-Hong Hong
Nov 7, 2020·Medicinal Research Reviews·Atif ZafarRuiwen Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.